타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 4개 · 임상 갱신 필요 4개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||||
|---|---|---|---|---|
Overview Program | Avastin (bevacizumab) | Erbitux (cetuximab) | Tisotumab Vedotin | Toripalimab |
Overview Company | Roche / Genentech | Eli Lilly / Merck KGaA | Genmab / Pfizer | Junshi Biosciences |
Overview Modality | ANTIBODY | ANTIBODY | ADC | ANTIBODY |
Overview Target | VEGF-A | EGFR | Solid Malignancies | Gastric Cancer |
Overview Indication | US label: colorectal, non-squamous NSCLC, glioblastoma, renal, cervical and ovarian cancers; regimen-specific indications | US label: head and neck squamous cell cancer and biomarker-selected colorectal cancer; regimen-specific indications | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Metastatic Colorectal Cancer; Liver Metastases |
Overview Phase | APPROVED | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | novel NaPi2b-targeting ADC YL205 in heavily pretreated platinum-resistant ovarian cancer | novel strategies of biotherapeutics | — | novel safety signals were identified |
Positioning Known limitation | downregulation across different drug combinations | resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models | — | downregulation of p-Akt and Ki-67 |
MoA Mechanism | target proteins (DHFR, TGF-1beta, estrogen receptor | targeting the epidermal growth factor receptor | — | Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production |
MoA Biomarker | biomarker angiopoietin-2 (Ang-2), producing effects similar to the Wnt/β-catenin inhibitor (dickkopf-re | EGFR SR could be established with high | — | PD-L1)-positive |
Toxicology Major finding | — | — | Pneumonitis: Severe, life-threatening, or fatal pneumonitis may occur | — |
Clinical Safety signal | — | — | Pneumonitis: Severe, life-threatening, or fatal pneumonitis may occur | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 4개 · 임상 갱신 필요 4개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||||
|---|---|---|---|---|
Overview Program | Avastin (bevacizumab) | Erbitux (cetuximab) | Tisotumab Vedotin | Toripalimab |
Overview Company | Roche / Genentech | Eli Lilly / Merck KGaA | Genmab / Pfizer | Junshi Biosciences |
Overview Modality | ANTIBODY | ANTIBODY | ADC | ANTIBODY |
Overview Target | VEGF-A | EGFR | Solid Malignancies | Gastric Cancer |
Overview Indication | US label: colorectal, non-squamous NSCLC, glioblastoma, renal, cervical and ovarian cancers; regimen-specific indications | US label: head and neck squamous cell cancer and biomarker-selected colorectal cancer; regimen-specific indications | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Metastatic Colorectal Cancer; Liver Metastases |
Overview Phase | APPROVED | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | novel NaPi2b-targeting ADC YL205 in heavily pretreated platinum-resistant ovarian cancer | novel strategies of biotherapeutics | — | novel safety signals were identified |
Positioning Known limitation | downregulation across different drug combinations | resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models | — | downregulation of p-Akt and Ki-67 |
MoA Mechanism | target proteins (DHFR, TGF-1beta, estrogen receptor | targeting the epidermal growth factor receptor | — | Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production |
MoA Biomarker | biomarker angiopoietin-2 (Ang-2), producing effects similar to the Wnt/β-catenin inhibitor (dickkopf-re | EGFR SR could be established with high | — | PD-L1)-positive |
Toxicology Major finding | — | — | Pneumonitis: Severe, life-threatening, or fatal pneumonitis may occur | — |
Clinical Safety signal | — | — | Pneumonitis: Severe, life-threatening, or fatal pneumonitis may occur | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
추천 비교
추천 비교